PCM
EW icon

Prelude Capital Management’s Edwards Lifesciences EW Stock Holding History

Prelude Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed -$19K – 1796
2019
Q1 		$19K Buy
+300
New +$17.1K ﹤0.01% 1322

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Prelude Capital Management's EW Position: Q1 2024 in Review

Prelude Capital Management sold out of Edwards Lifesciences (EW) in Q1 2024, closing a stake of 2,861 shares — an estimated $218K sold.

Prelude Capital Management first reported a position in EW in Q2 2013 and held it in 29 quarters. The position peaked at $1.72M in Q3 2014. 1,280 funds tracked by Wall St. Rank hold EW as of Q1 2024.

  • Prelude Capital Management reported no remaining Edwards Lifesciences position as of Q1 2024 after selling out during the quarter.
  • Prelude Capital Management sold 2,861 Edwards Lifesciences shares in Q1 2024, an estimated $218K.
  • Prelude Capital Management first reported a position in Edwards Lifesciences in Q2 2013 and held it in 29 quarters.
  • Prelude Capital Management's Edwards Lifesciences position peaked at $1.72M in Q3 2014.
  • 1,280 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2024.

Based on Prelude Capital Management's 13F filing for Q1 2024, filed 15 May 2024.